
Novartis narrowed its mid-term sales growth outlook to 5% annually through 2031 at its London investor day, as patent expirations weigh on the Swiss drugmaker.
Technology offers the promise of engaging patients on a level never seen before.
Technology offers the promise of engaging patients on a level never seen before. The benefits of an engaged patient start with increased compliance-a great thing for pharmaceutical companies-and extend to a more active and empowered consumer of healthcare, and ultimately to better and more affordable outcomes.
But technology is a double-edged sword. Its increasing complexity leads to increasing risk and greater scrutiny.
So what does this mean to Senior Directors and Franchise Leaders at pharmaceutical companies?






